入组前液体类型、入院类型与平衡晶体液对危重成人疗效的关联:BaSICS试验的二次探索性分析
该研究为BaSICS试验的二次事后分析,纳入10,520例ICU患者,按入组前24小时液体使用情况分为仅平衡液、仅0.9%盐水、两者混合、未用液体四组,按入院类型分为计划入院、非计划脓毒症入院、非计划非脓毒症入院。采用分层逻辑贝叶斯模型评估随机分组与90天死亡率的关联。全试验人群平衡液改善90天死亡率的概率低(OR 0.95;89%CrI 0.66-10.51;获益概率0.58);但入组前仅接受平衡液者获益概率高(OR 0.78;89%CrI 0.56-1.03;获益概率0.92),主要来自非计划脓毒症入院(OR 0.70;89%CrI 0.50-0.97;获益概率0.96)和计划入院(OR 0.79;89%CrI 0.65-0.97;获益概率0.97)。
要点
- 全试验人群:平衡液与90天死亡率改善的关联概率低(OR 0.95;89%CrI 0.66-10.51;获益概率0.58)。
- 入组前仅用平衡液者:ICU使用平衡液获益概率高(OR 0.78;89%CrI 0.56-1.03;获益概率0.92),不受入院类型影响。
- 非计划脓毒症入院亚组:平衡液与90天死亡率降低相关(OR 0.70;89%CrI 0.50-0.97;获益概率0.96)。
- 计划入院亚组:平衡液与90天死亡率降低相关(OR 0.79;89%CrI 0.65-0.97;获益概率0.97)。
- 该分析为BaSICS试验的二次事后探索性分析,结果需谨慎解读。
适用人群与场景
- BaSICS试验纳入的ICU危重成人患者,共10,520例。
- 按入组前24小时液体使用分为四组:仅平衡液、仅0.9%盐水、两者混合、未用液体。
- 按入院类型分为:计划入院、非计划脓毒症入院、非计划非脓毒症入院。
研究设计与关键结果
- 研究类型:BaSICS试验的二次事后探索性分析;BaSICS试验比较平衡液(Plasma-Lyte 148)与0.9%盐水在ICU患者中的效果。
- 样本量:共纳入10,520例患者。
- 主要终点:90天死亡率;采用分层逻辑贝叶斯模型评估随机分组与90天死亡率的关联。
- 全试验人群:平衡液与90天死亡率改善的关联概率低(OR 0.95;89%CrI 0.66-10.51;获益概率0.58)。
- 入组前仅接受平衡液者:获益概率高(OR 0.78;89%CrI 0.56-1.03;获益概率0.92),不受入院类型影响。
- 非计划脓毒症入院亚组:OR 0.70;89%CrI 0.50-0.97;获益概率0.96。
- 计划入院亚组:OR 0.79;89%CrI 0.65-0.97;获益概率0.97。
证据类型、等级与局限
- 证据类型:随机对照试验(BaSICS)的二次事后探索性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在ICU中使用平衡液可能降低入组前仅接受平衡液患者的90天死亡率(OR 0.78;89%CrI 0.56-1.03;获益概率0.92)。
- 该分析为二次事后探索性分析,原文结论未据此给出常规推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: The effects of balanced crystalloid versus saline on clinical outcomes for ICU patients may be modified by the type of fluid that patients received for initial resuscitation and by the type of admission. Objectives: To assess whether the results of a randomized controlled trial could be affected by fluid use before enrollment and admission type. Methods: Secondary post hoc analysis of the BaSICS (Balanced Solution in Intensive Care Study) trial, which compared a balanced solution (Plasma-Lyte 148) with 0.9% saline in the ICU. Patients were categorized according to fluid use in the 24 hours before enrollment in four groups (balanced solutions only, 0.9% saline only, a mix of both, and no fluid before enrollment) and according to admission type (planned, unplanned with sepsis, and unplanned without sepsis). The association between 90-day mortality and the randomization group was assessed using a hierarchical logistic Bayesian model. Measurements and Main Results: A total of 10,520 patients were included. There was a low probability that the balanced solution was associated with improved 90-day mortality in the whole trial population (odds ratio [OR], 0.95; 89% credible interval [CrI], 0.66-10.51; probability of benefit, 0.58); however, probability of benefit was high for patients who received only balanced solutions before enrollment (regardless of admission type, OR, 0.78; 89% CrI, 0.56-1.03; probability of benefit, 0.92), mostly because of a benefit in unplanned admissions due to sepsis (OR, 0.70; 89% CrI, 0.50-0.97; probability of benefit, 0.96) and planned admissions (OR, 0.79; 89% CrI, 0.65-0.97; probability of benefit, 0.97). Conclusions: There is a high probability that balanced solution use in the ICU reduces 90-day mortality in patients who exclusively received balanced fluids before trial enrollment. Clinical trial registered with www.clinicaltrials.gov (NCT02875873).
参考来源
- Zampieri FG, Machado FR, Biondi RS, et al. Association between Type of Fluid Received Prior to Enrollment, Type of Admission, and Effect of Balanced Crystalloid in Critically Ill Adults: A Secondary Exploratory Analysis of the BaSICS Clinical Trial. Am J Respir Crit Care Med. 2022. PMID: 35349397. doi:10.1164/rccm.202111-2484OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。